Ligand id: 5039


Species: Human

No information available.
Summary of Clinical Use
Used in the topical treatment of skin ulcers caused by diabetes. Marketing approval for the Regranex® brand has been discontinued in the EU, but the Gemesis® brand still has approval to promote tissue regeneration in adults with periodontal defects.
Mechanism Of Action and Pharmacodynamic Effects
An agonist binding to the platelet-derived growth factor receptor (PDGFR). PDGF-BB is the highest-affinity ligand for PDGFRβ and this interaction may be be responsible for the promotion of fibrotic healing observed when using this drug.
External links